Radiomics-based prediction of response to multikinase inhibitors in radioiodine-refractory differentiated thyroid cancer patients. Trastuzumab deruxtecan (T-DXd) in patients with human epidermal ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Here, we describe the ability of LOXO-292 to overcome acquired RET kinase domain mutations preclinically and in two patients with RET-altered cancers, one with acquired gatekeeper mutation resistance ...
Xueqing Hu , Ujjwol Khatri , Tao Shen , and Jie Wu, at University of Oklahoma Health Sciences Center, USA, provides a comprehensive review of the role of the RET (REarranged during Transfection) ...
Traditional approval establishes confirmed clinical benefit for selpercatinib in tumor-agnostic RET fusion–positive solid tumors after progression or when no satisfactory options exist. LIBRETTO-001 ...
The US drugmaker has launched Tanstrive, a RET-targeted oral therapy for advanced or metastatic solid tumours, following marketing authorisation from the CDSCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results